CLINICAL OUTCOMES AFTER TWO YEARS OF A TREAT-TO-DRUG-FREE REMISSION STRATEGY WITH TOCILIZUMAB INCLUDING TREATMENT DISCONTINUATION FOLLOWING SUSTAINED REMISSION IN THE ACT-RAY STUDY (ENCORE)